These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8189029)

  • 41. New approaches may aid patients with inflammatory bowel disease.
    Cotton P
    JAMA; 1990 Jun; 263(23):3121-2. PubMed ID: 2348514
    [No Abstract]   [Full Text] [Related]  

  • 42. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers.
    Sandborn WJ; Hanauer SB; Buch A
    Aliment Pharmacol Ther; 2004 May; 19(10):1089-98. PubMed ID: 15142198
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Asacol in inflammatory bowel disease.
    Oakes RA
    N Z Med J; 1987 May; 100(824):325. PubMed ID: 3451096
    [No Abstract]   [Full Text] [Related]  

  • 44. Aminosalicylates for the treatment of inflammatory bowel disease.
    Leichtner AM
    J Pediatr Gastroenterol Nutr; 1995 Oct; 21(3):245-52. PubMed ID: 8523207
    [No Abstract]   [Full Text] [Related]  

  • 45. Sulfasalazine and new analogues in inflammatory bowel disease, with focus on Crohn's disease.
    van Hees PA
    Acta Gastroenterol Belg; 1987; 50(5):555-9. PubMed ID: 2902723
    [No Abstract]   [Full Text] [Related]  

  • 46. [False melanuria in a female patient treated with 5-ASA for ulcerative colitis].
    Cuende JI; Gómez MT; García M; Pérez IJ
    Med Clin (Barc); 1995 May; 104(20):798. PubMed ID: 7783478
    [No Abstract]   [Full Text] [Related]  

  • 47. Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.
    Brogden RN; Sorkin EM
    Drugs; 1989 Oct; 38(4):500-23. PubMed ID: 2684592
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mesalazine during pregnancy.
    Marteau P; Devaux CB
    Lancet; 1994 Dec; 344(8938):1708-9. PubMed ID: 7996988
    [No Abstract]   [Full Text] [Related]  

  • 49. Are mesalazine granules superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis?
    Brooks AJ; Lobo AJ
    Aliment Pharmacol Ther; 2012 Jan; 35(1):193-4. PubMed ID: 22150535
    [No Abstract]   [Full Text] [Related]  

  • 50. [New salicylic acid derivatives in the treatment of inflammatory intestinal diseases].
    Kovács A
    Orv Hetil; 1991 Jun; 132(24):1317-21. PubMed ID: 1677465
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Changing treatment of inflammatory bowel diseases].
    Karvonen AL; Matikainen M; Turunen U
    Duodecim; 1994; 110(20):1945-54. PubMed ID: 7555809
    [No Abstract]   [Full Text] [Related]  

  • 52. Eudragit FS 30 D: a new pH-sensitive polymer covering for mesalamine.
    Potestà P
    Eur Rev Med Pharmacol Sci; 2001; 5(1):30. PubMed ID: 11860220
    [No Abstract]   [Full Text] [Related]  

  • 53. Mesalazine-associated interstitial nephritis.
    World MJ; Stevens PE; Ashton MA; Rainford DJ
    Nephrol Dial Transplant; 1996 Apr; 11(4):614-21. PubMed ID: 8671848
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. International Mesalazine Study Group.
    Aliment Pharmacol Ther; 1990 Feb; 4(1):55-64. PubMed ID: 2104074
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Aminosalicylates in the treatment of chronic inflammatory bowel diseases].
    Hartmann F; Plauth M
    Internist (Berl); 1990 Nov; 31(11):702-6. PubMed ID: 2289856
    [No Abstract]   [Full Text] [Related]  

  • 56. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease.
    Prantera C; Pallone F; Brunetti G; Cottone M; Miglioli M;
    Gastroenterology; 1992 Aug; 103(2):363-8. PubMed ID: 1634054
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 5-Aminosalicylic acid in the treatment of inflammatory bowel disease.
    Bondesen S; Rasmussen SN; Rask-Madsen J; Nielsen OH; Lauritsen K; Binder V; Hansen SH; Hvidberg EF
    Acta Med Scand; 1987; 221(3):227-42. PubMed ID: 3296672
    [No Abstract]   [Full Text] [Related]  

  • 58. Sulfasalazine desensitization in children and adolescents with chronic inflammatory bowel disease.
    Tolia V
    Am J Gastroenterol; 1992 Aug; 87(8):1029-32. PubMed ID: 1353658
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Conditions for applying enteric coatings based on Eudragit L 30 D].
    Dechesne JP; Delporte JP; Jaminet F; Venturas K
    J Pharm Belg; 1982; 37(4):273-82. PubMed ID: 7143200
    [No Abstract]   [Full Text] [Related]  

  • 60. Treatment of inflammatory bowel disease: safety and tolerability issues.
    Navarro F; Hanauer SB
    Am J Gastroenterol; 2003 Dec; 98(12 Suppl):S18-23. PubMed ID: 14697914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.